Key Highlights

  • On the screen, Amneal Pharmaceuticals (NASDAQ:AMRX) trades at USD 20.44, down 4.97% from a 52-week peak of USD 21.68, with a Market Capitalisation of USD 7.12 billion. Every figure here is unverified screener data.
  • Third-quarter 2026 results, released on November 3, 2026, delivered net Revenue of USD 863 million, up 10%, adjusted EBITDA of USD 207 million, up 30%, and adjusted diluted EPS of USD 0.26, up 53%.
  • On a GAAP basis, Amneal posted a loss of USD 22 million, or USD 0.06 per share, compared with Net Income of USD 2 million a year earlier. The company blamed one-off costs tied to the Kashiv Acquisition and a larger tax charge.
  • Guidance for 2026 net revenue was lifted to USD 3.15 billion to USD 3.25 billion and adjusted EPS to USD 1.04 to USD 1.08, while Operating Cash Flow guidance was trimmed to USD 325 million to USD 375 million from USD 350 million to USD 400 million.

What the Report Showed

Amneal Pharmaceuticals (NASDAQ:AMRX) makes and sells generics, injectables, Biosimilars and specialty branded drugs. Affordable Medicines sales climbed 19% to USD 547 million, driven by biosimilars, women's health patches and new launches. Specialty sales grew 20% to USD 150 million on CREXONT, BREKIYA and UNITHROID. AvKARE sales dropped 17% to USD 165 million, as anticipated, given a one-time cardiovascular launch the year before. The Kashiv BioSciences deal closed around August 10, 2026. Published market data put the 52-week range at USD 9.99 to USD 21.18 on October 26, 2026. Around September 18, 2026, the company also received FDA approval for its lanreotide injection and began selling it.

Why a Stock Can Touch a High and Then Fall

A 52-week high marks the top of a one-year price band. A share that has climbed hard, here from USD 9.99 to above USD 21, may slip on good news if buyers expected even more. Simple arithmetic on USD 20.44 and USD 9.99 puts the price roughly double the low. This research found no confirmed trigger for the 4.97% decline. A reader might weigh the GAAP loss, a softer operating cash flow outlook, the AvKARE slump and the expected rise in capital spending to about USD 150 million, but these are possible readings rather than confirmed causes. After a strong run into earnings, plenty of good news may already be priced in.

Risks and What to Watch

Adjusted EPS of USD 0.26 sits below the USD 0.30 posted in the second quarter, which some readers may treat as a sequential slowdown. Third-quarter consensus was not verified here. Before the report, analysts were upbeat: JPMorgan lifted its target to USD 24 from USD 22, and Oppenheimer initiated coverage at Outperform with a USD 27 target. Generic drug pricing, biosimilar rivalry and the Kashiv integration are the main hazards, and a law firm announced a Shareholder investigation in July. The screen P/E of 42.65 is unverified. Keep an eye on cash conversion and the fourth-quarter outlook, and check the Cash Flow Statement in the full report.

Where Things Stand

Amneal dropped 4.97% after hitting a 52-week peak, and the cause has not been confirmed. The report cuts both ways: revenue rose 10%, adjusted EBITDA jumped 30% and revenue and EPS guidance went up, while the GAAP loss, weaker AvKARE sales and lower operating cash flow guidance pull the other way. With the shares about double their 52-week low, expectations were elevated. The next dated event is the fourth-quarter report, though no date is confirmed. Any recovery will hinge on cash conversion and biosimilar launches. The revenue and EPS guidance raise is positive, but cash conversion will determine how investors judge it.